Fresh analysis suggests that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who stop conventional lifestyle regimens.
Published data in a leading medical journal points out that while obese people frequently drop about a fifth of their body weight while on the medication, the weight returns at an estimated rate of nearly a kilo each month once they quit.
"People buying such treatments must be cognizant of the potential of rapid weight regain when the medication concludes," cautioned researcher Dr. Susan Jebb.
This pace of recovery implies a reversion to original weight in about 18 months.
Analyzing Treatments
The analysis, which looked at dozens of trials involving thousands of patients, contrasted the results of these new drugs with older methods.
Researchers emphasize that individuals who lose weight through diet and exercise usually see a slower weight regain—around 0.1 kg a month—after stopping.
The Reason for the Rapid Rebound
Experts suggest the way of the injections accounts for the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of the hormone concentrations far above than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a nutrition researcher.
"Discontinuation of this hormone supplement results in hunger is unsuppressed, making binge eating much more probable."
A Lifelong Issue?
The NHS suggest the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the significant potential of weight regain, the therapy is often life-long.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," similar to managing conditions like hypertension.
User Accounts
Individuals who have discontinued the medication explain a powerful return of cravings.
"I experienced something flipping and you become starving," described a patient.
This challenge is exacerbated if individuals have not adopted sustainable dietary or behavioural modifications during treatment.
Growing Use
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the last 12 months, with desire being substantial.
- Use is higher among women than men.
- The middle-aged demographic shows the highest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and maintained weight loss relies on ongoing behavioural management.
